VTB-10

VTB-10 is a first-in-class drug candidate developed by Vasthera using its proprietary Redoxizyme platform for the treatment of pulmonary arterial hypertension (PAH), a rare and progressive disease characterized by elevated blood pressure in the lung arteries. VTB-10 is a small molecule enzyme ("Chemzyme") designed to precisely replicate peroxiredoxin (PRX) function, an enzyme found deficient in PAH lesions. Mechanistically, VTB-10 works by inhibiting intimal hyperplasia through targeting **PDGFR signaling** in pulmonary arterial smooth muscle cells and promoting re-endothelialization by restoring **VEGFR2 signaling** in pulmonary arterial endothelial cells. Preclinical studies have demonstrated that VTB-10 can reverse abnormal vascular remodeling and restore functional endothelium, thereby normalizing pulmonary artery structure and function[1][2][4][6][8].